StageZero Life Sciences Ltd. (SZLSF) Comparison with companies in other sectors?

StageZero Life Sciences Ltd. has a share price of 123.55M. You can analyze StageZero Life Sciences Ltd. (SZLSF) competitors across different market sectors through stock heatmaps.

What are SZLSF's NET and operating margins?

StageZero Life Sciences Ltd. (SZLSF) operating margin is around -0.97, and net profit margin is approximately -1.02 as of the latest reports.

In what way does SZLSF's earnings per share (EPS) trend reflect its financial momentum?

StageZero Life Sciences Ltd. (SZLSF) EPS is -0.12 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for StageZero Life Sciences Ltd. is -0.16, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for StageZero Life Sciences Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for StageZero Life Sciences Ltd. like P/E which is -1.64, P/B which is -0.21, and PEG which is -3.01. Compare them with sector averages to evaluate if the stock is priced fairly.

StageZero Life Sciences Ltd.

SZLSF•PNK

Healthcare

Medical - Diagnostics & Research

$0.02

$0.005(30.000%)

StageZero Life Sciences Ltd. (SZLSF) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.12

P/E Ratio

-0.16

ROE

0.13%

Net Margin

-1.02%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.35M

Shares OutstandingTotal number of shares issued

$123.55M

Book Value/ShareNet worth per share

$-0.09

Revenue/ShareAnnual revenue per share

$0.01

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.12

Net MarginNet income as percentage of revenue

-101.70%

Operating MarginOperating income as percentage of revenue

-96.65%

ROEReturn on shareholders' equity

13.42%

ROAReturn on total assets

-246.81%

ROCEReturn on capital employed

13.98%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.00

Cash/ShareCash and equivalents per share

$0.00

FCF YieldFree cash flow as percentage of market cap

-6.18%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SZLSFFinancial Ratios Analysis details for SZLSF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SZLSFSector Benchmarking details for SZLSF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for StageZero Life Sciences Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of StageZero Life Sciences Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account StageZero Life Sciences Ltd.'s unique business strengths and challenges.

Key Financial Metrics for StageZero Life Sciences Ltd.

For StageZero Life Sciences Ltd., essential financial indicators include EPS -0.12, PE -0.16, and ROE 0.13. These key ratios reveal insights into StageZero Life Sciences Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare StageZero Life Sciences Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of StageZero Life Sciences Ltd.

Metrics like Net Margin -101.70% and ROA -246.81% shed light on how well StageZero Life Sciences Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether StageZero Life Sciences Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of StageZero Life Sciences Ltd.

Using ratios such as P/B Ratio -0.21 and PEG Ratio -3.01, investors can assess whether StageZero Life Sciences Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with StageZero Life Sciences Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for StageZero Life Sciences Ltd.

Financial health indicators, such as Debt/Equity Ratio -0.19 and Cash Flow $-0.00, provide a snapshot of StageZero Life Sciences Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like StageZero Life Sciences Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for StageZero Life Sciences Ltd.

Investing in StageZero Life Sciences Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at StageZero Life Sciences Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;